Product Description
Mechanisms of Action: FXII Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Regeneron
Company Location: Eastern America
Company Founding Year: 1988
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06669234 |
ALN-F1202-HV-2412 | P1 |
Active, not recruiting |
Healthy Volunteers |
2026-07-30 |
88% |
2026-02-24 |
Recent News Events
Date |
Type |
Title |
|---|